Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Lineage Cell Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +5 vs. Q2 2022
- Shares held
- 64.7M
- −260.2K (−0.4%) vs. Q2 2022
- Total value
- $73.1M
- −$29.5M (−28.8%) vs. Q2 2022
- New holders
- 16
- 17 more added
- Sold out
- 11
- 28 more reduced
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 131 | $152.7M |
| Q1 2026 | 130 | $176.5M |
| Q4 2025 | 123 | $169.8M |
| Q3 2025 | 112 | $148.6M |
| Q2 2025 | 129 | $88.4M |
| Q1 2025 | 127 | $49.7M |
| Q4 2024 | 126 | $53.8M |
| Q3 2024 | 114 | $85.6M |
| Q2 2024 | 113 | $94.2M |
| Q1 2024 | 116 | $138.3M |
| Q4 2023 | 115 | $82.5M |
| Q3 2023 | 104 | $89.1M |
| Q2 2023 | 107 | $106.6M |
| Q1 2023 | 116 | $104.7M |
| Q4 2022 | 106 | $76.2M |
| Q3 2022 | 104 | $73.1M |
| Q2 2022 | 100 | $102.7M |
| Q1 2022 | 109 | $112.3M |
| Q4 2021 | 124 | $182.0M |
| Q3 2021 | 115 | $191.7M |
| Q2 2021 | 115 | $208.5M |
| Q1 2021 | 102 | $141.8M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Defender Capital, LLC. | 5,184,035 | $5.86M | 2.30% | +52,100+1.0% | Added |
| Vanguard Group Inc | 5,951,493 | $6.73M | 0.00% | 00.0% | Unchanged |
| Broadwood Capital Inc | 34,935,485 | $39.5M | 3.01% | 00.0% | Unchanged |
| IFP Advisors, Inc | 8 | – | – | 00.0% | Unchanged |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −44,829−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −27,777−100.0% | Sold out |
| Morgan Jess S & Co Inc | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −10,886−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −10,432−100.0% | Sold out |
| Integrated Wealth Concepts LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Concord Wealth Partners | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −907−100.0% | Sold out |
| Proffitt & Goodson Inc | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Capital Advisors, Ltd. LLC | 0 | $0 | 0.00% | −38−100.0% | Sold out |
| Curi Capital | 0 | $0 | 0.00% | −51−100.0% | Sold out |
| Quadrant Private Wealth Management, LLC | – | – | – | – | Not filed |